Verisk Analytics (VRSK) has been in focus after its recent annual meeting, where shareholders approved a proposal to allow action by written consent and backed a refreshed board. This outcome underscores active interest in the company’s governance.
See our latest analysis for Verisk Analytics.
Despite the governance changes and board refresh, Verisk’s share price has been under pressure, with the 90 day share price return down 12.62% and the 1 year total shareholder return down 45.46%. This suggests momentum has been fading even as investors reassess growth potential and risks.
If this kind of governance story has you rethinking your portfolio mix, it could be a good time to widen your research and check out 20 top founder-led companies
So with Verisk’s share price under pressure and some models pointing to a discount to estimated value, is the stock genuinely undervalued at this level, or is the market already factoring in its future growth potential?
Most Popular Narrative: 145.5% Overvalued
Verisk’s last close of $171.11 sits well above the fair value of $69.70 implied by the most followed narrative, which argues the stock price runs ahead of fundamentals according to Esteban.
Verisk Analytics is a regulatory-grade data toll on the US property & casualty insurance industry, monetized through ~83% subscription revenue with ~92% client retention. VRSK's narrow-moat franchise produces FCF with an unusually high degree of predictability, durable enough to justify a 15× exit multiple at a 35% margin of safety. The 2022 to 2025 portfolio simplification (Energy, Argus, 3E, Marketing Solutions all divested) has produced a cleaner pure-play with structurally higher margins (Adj EBITDA 56.2% in 2025 vs. 53.5% in 2023) and a shrinking share count (~19% reduction since 2019). What the investor is paying for here is a regulatory annuity with an embedded MSD price-and-volume escalator, and walking away from any thesis premised on this becoming a HSD to DD revenue compounder.
Want to see how a slow and steady revenue profile still leads to such a low fair value? The tension lies in margin assumptions and the terminal multiple. Curious which cash flow trajectory Esteban uses to justify that discount?
Result: Fair Value of $69.70 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this view could be knocked off course if pricing power weakens in key insurance datasets or if margin expectations fall short of the projected profile.
Find out about the key risks to this Verisk Analytics narrative.
Another View: Market Ratios Tell a Different Story
Esteban’s narrative points to a fair value of $69.70, yet the current trading price of $171.11 aligns more closely with how the market prices peers. Verisk’s P/E of 24.6x is below the peer average of 29.4x and almost exactly in line with its fair ratio of 24.7x, which suggests less obvious mispricing than that deep discount narrative implies. The core question is whether the real tension lies between market consensus and a single, much lower fair value estimate.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After reading both the discount narrative and the market multiple view, you can see sentiment is split. Move quickly, review the full picture, and weigh 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If Verisk has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas that match the way you like to invest.
- Target potential value opportunities by scanning through companies that appear overlooked using 48 high quality undervalued stocks
- Prioritise resilience by filtering for businesses that show stronger finances with the solid balance sheet and fundamentals stocks screener (46 results)
- Stay ahead of the crowd by spotting lesser known prospects through a screener containing 21 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com